What's breaking now, across thousands of outlets.
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.
Rivian's R2 is now its best-selling vehicle, which could put the company one step closer to profitability.
One's a 103-year-old toy maker. The other's a cruise line that caters to a cultured crowd. Both are near the end of a banner year, and the next two decades look even better.
Key PointsInternational cannabis net revenue grew 141% year over year to $12.3 million.
